More U.S. investors are launching companies stateside that license technology from China, even as Congress moves to crack down on some Chinese companies through the BIOSECURE Act. Read more.
Cassava Sciences ( (SAVA) ) has released its Q3 earnings. Here is a breakdown of the information Cassava Sciences presented to its investors.
Cassava Sciences' stock is highly shorted, with potential reward tied to the upcoming Phase 3 trial results for simufilam.
Cassava Sciences' RETHINK-ALZ trial is nearing data release. See why SAVA stock could see volatility depending on trial ...
College of Agriculture and Food Technology (CoAF) in Lindi Region is poised to revolutionise agriculture in southern Tanzania ...
Today, Benzinga's options scanner spotted 8 options trades for Cassava Sciences. This isn't normal. The overall sentiment of ...
Top-line Data for RETHINK-ALZ 52-week Phase 3 trial Expected Before the End of 2024 $149.0 Million in Cash and Cash ...
When research on an intriguing material called for hundreds of samples, secondary-school students, teachers and technicians stepped up.
Cassava then released the altered data in a press release and investor deck, which led the SEC to allege that the company and ...
Today, Benzinga 's options scanner spotted 11 uncommon options trades for Cassava Sciences. This isn't normal. The overall ...
Generic drugmaker Accord Healthcare has announced a £50 million ($65 million) investment in the UK that will include the ...
Bearish flow noted in Cassava Sciences (SAVA) with 2,978 puts trading, or 1.3x expected. Most active are Nov-24 27 puts and Dec-24 10 puts, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback